ArticlemBio2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant
Open access · goldAbstract read
In one paragraph
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 31% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Resistance of different antimicrobials to CRKP: a meta analysis.BMC infectious diseases · 2026Pooled it
- Organic acid-based deep eutectic solvents (DESs) are potent antimicrobial agents against antibiotic-resistant bacteria and viruses.Current research in microbial sciences · 2026Article
- Antimicrobial resistance inScience in One Health · 2025Review
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors inAntimicrobial agents and chemotherapy · 2024Article
- Drug Discovery in the Field of β-Lactams: An Academic Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology.Antimicrobial agents and chemotherapy · 2023Article
- PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.Microbiology spectrum · 2023Article
- Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.Antimicrobial agents and chemotherapy · 2022Article
- Role of Chromosome- and/or Plasmid-LocatedMicrobiology spectrum · 2022Article
- Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.Antimicrobial agents and chemotherapy · 2022Article
- The Whole Is Bigger than the Sum of Its Parts: Drug Transport in the Context of Two Membranes with Active Efflux.Chemical reviews · 2021Article
- Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.Clinical pharmacology and therapeutics · 2021Article
- First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2020Article
- Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.Pathogens (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 4 countries.
Tae Hwan Kim *Departments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Xun Tao *Departments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Bartolome MoyaDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-6404-246X
Yuanyuan JiaoDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Kari B BassoDepartment of Chemistry, University of Florida, Gainesville, Florida, USA.
Jieqiang ZhouDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Yinzhi LangDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Dhruvitkumar S SutariaDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Alexandre P ZavasckiUniversidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Afonso L BarthUniversidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Stephanie M ReeveDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Herbert P SchweizerDepartment of Molecular Genetics and Microbiology, Emerging Pathogens Institute, College of Medicine, University of Florida, Gainesville, Florida, USA.
Deanna Deveson LucasInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Australia.
John D BoyceInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Australia.ORCID 0000-0002-8614-3074
Robert A BonomoMedical Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Richard E LeeDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Beom Soo ShinSchool of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
Arnold LouieInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
George L DrusanoInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
Jürgen B BulittaDepartments of Pharmaceutics and Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA jbulitta@cop.ufl.edu.ORCID 0000-0001-7352-3097
University of Florida · USAustralian Regenerative Medicine Institute · AUSt. Jude Children's Research Hospital · USUniversidade Federal do Rio Grande do Sul · BRGeriatric Research Education and Clinical Center · USSungkyunkwan University · KR
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MCombating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MNovel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsR01AI148560 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BULITTA, JURGEN BERND, TSUJI, BRIAN · 2020 to 2024
$3.9MNext-generation combination dosing strategies to combat resistant Acinetobacter baumanniiR01AI130185 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$3.4MAcquisition of a Q Exactive HF Hybrid Quadrupole-OrbitrapS10OD021758 · OD · UNIVERSITY OF FLORIDA · PI BASSO, KARI B · 2017 to 2017
$600kMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kNIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI130185NIAID NIH HHS R01 AI136803NIAID NIH HHS R01 AI148560NIAID NIH HHS R21 AI114508NIH HHS S10 OD021758
Abstract
Poor penetration through the outer membrane (OM) of Gram-negative bacteria is a major barrier of antibiotic development. While β-lactam antibiotics are commonly used against
Indexed as
Anti-Bacterial AgentsBacterial Outer Membranebeta-LactamsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsCell Membrane PermeabilityEnterobacter cloacaeKlebsiella pneumoniaeMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamsCarbapenemsbeta-lactamscarbapenem resistancecarbapenemscassette assaycephalosporinsEnterobacter cloacaeKlebsiella pneumoniaeLC-MS/MSmonobactamsouter membranepermeabilitypolymyxin resistance
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.